• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗精神病药物对智力障碍患者的副作用。

Antipsychotic drug side effects for persons with intellectual disability.

机构信息

Department of Psychology, Louisiana State University, Baton Rouge, LA 70803, USA.

出版信息

Res Dev Disabil. 2010 Nov-Dec;31(6):1570-6. doi: 10.1016/j.ridd.2010.05.005. Epub 2010 Jun 26.

DOI:10.1016/j.ridd.2010.05.005
PMID:20580203
Abstract

Antipsychotic drugs are the most frequently prescribed of the psychotropic drugs among the intellectually disabled (ID) population. Given their widespread use, efforts to systematically assess and report side effects are warranted. Specific scaling methods such as the Matson Evaluation of Side Effects (MEDS), the Abnormal Inventory Movement Scale (AIMS), and Dyskinesia Identification System Condensed User Scale (DISCUS) are reviewed. Symptom patterns and a focus on additional research are discussed. While progress has been made, more and more systematic methods to research these problems are necessary.

摘要

抗精神病药物是智障人群中最常开的精神药物。鉴于它们的广泛使用,有必要进行系统的评估和报告副作用的努力。本文回顾了特定的评估方法,如 Matson 效应评价量表(MEDS)、异常运动量表(AIMS)和运动障碍识别系统简化用户量表(DISCUS)。还讨论了症状模式和对额外研究的关注。虽然已经取得了进展,但仍需要更多系统的方法来研究这些问题。

相似文献

1
Antipsychotic drug side effects for persons with intellectual disability.抗精神病药物对智力障碍患者的副作用。
Res Dev Disabil. 2010 Nov-Dec;31(6):1570-6. doi: 10.1016/j.ridd.2010.05.005. Epub 2010 Jun 26.
2
The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).《药物副作用的马特森评估量表(MEDS)》与《异动症识别系统:简明用户量表(DISCUS)》的收敛效度和区分效度。
J Intellect Dev Disabil. 2008 Dec;33(4):337-44. doi: 10.1080/13668250802478799.
3
Tardive dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use.迟发性运动障碍和智力障碍:双重诊断和使用非典型抗精神病药物的成年人的人口统计学和发病部位研究。
Res Dev Disabil. 2010 May-Jun;31(3):750-9. doi: 10.1016/j.ridd.2010.01.017. Epub 2010 Mar 5.
4
Current status of the Matson Evaluation of Drug Side Effects (MEDS).Matson 药物不良反应评估(MEDS)的现状。
Res Dev Disabil. 2013 May;34(5):1849-53. doi: 10.1016/j.ridd.2013.02.030. Epub 2013 Mar 24.
5
Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?精神发育迟滞患者攻击行为的药物治疗:治疗还是虐待?
J Intellect Disabil Res. 2010 Jan 1;54(1):1-16. doi: 10.1111/j.1365-2788.2009.01232.x. Epub 2009 Dec 8.
6
An Examination of Psychotropic Medication Side Effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID?精神药物副作用的研究:成年人服用更多种类的精神药物是否会影响副作用的表现?
Res Dev Disabil. 2010 Nov-Dec;31(6):1561-9. doi: 10.1016/j.ridd.2010.05.006. Epub 2010 Jun 9.
7
Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription.抗精神病药物在荷兰智障(ID)个体中的使用:处方的流行率和原因。
J Intellect Disabil Res. 2010 Jul;54(7):659-67. doi: 10.1111/j.1365-2788.2010.01275.x. Epub 2010 Apr 20.
8
Akathisia in adults with severe and profound intellectual disability: a psychometric study of the MEDS and ARMS.重度和极重度智力残疾成年人的静坐不能:MEDS和ARMS的心理测量学研究
J Intellect Dev Disabil. 2008 Jun;33(2):171-6. doi: 10.1080/13668250802065190.
9
The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.运动障碍识别系统简明用户量表(DISCUS):针对精神疾病患者和智力障碍人群的信度、效度及总分临界值
J Clin Psychol. 1993 Mar;49(2):177-89.
10
Systematic dyskinesia examination of profoundly mentally retarded persons: cooperation and assessment.极重度智力障碍者的系统性运动障碍检查:合作与评估
Am J Ment Defic. 1987 Sep;92(2):155-60.

引用本文的文献

1
Description of Common Ailments and Nonprescription Medications Found in Medication Reviews for People With Intellectual Disability.智障人士药物评价中常见疾病及非处方药的描述。
J Intellect Disabil Res. 2025 Jul;69(7):613-620. doi: 10.1111/jir.13243. Epub 2025 Apr 24.
2
An evaluation of a multidisciplinary care planning tool for people with intellectual disabilities and behaviours of concern.对一种针对智障人士及相关问题行为的多学科护理规划工具的评估。
Int J Soc Psychiatry. 2025 Jun;71(4):655-669. doi: 10.1177/00207640241299395. Epub 2024 Nov 29.
3
A 10-Year Review on Advancements in Identifying and Treating Intellectual Disability Caused by Genetic Variations.
一项关于鉴定和治疗遗传变异引起的智力障碍的十年进展回顾。
Genes (Basel). 2024 Aug 24;15(9):1118. doi: 10.3390/genes15091118.
4
Reducing challenging behaviours among children and adolescents with intellectual disabilities in community settings: a systematic review of interventions.减少社区环境中智障儿童和青少年的挑战性 行为:干预措施的系统评价
Int J Dev Disabil. 2022 Mar 28;70(1):20-39. doi: 10.1080/20473869.2022.2052416. eCollection 2024.
5
Aligning quality of life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour.使智力残疾和具有挑战行为的成年人的生活质量与非标签使用精神药物指南保持一致。
Int J Dev Disabil. 2023 May 17;69(3):398-413. doi: 10.1080/20473869.2023.2195721. eCollection 2023.
6
Withdrawing Antipsychotics for Challenging Behaviours in Adults with Intellectual Disabilities: Experiences and Views of Prescribers.抗精神病药撤药治疗智力障碍成人行为问题:处方者的经验和观点。
Int J Environ Res Public Health. 2022 Dec 19;19(24):17095. doi: 10.3390/ijerph192417095.
7
Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review.评估药物在智力障碍患者中不良反应的量表:综述。
Eur J Clin Pharmacol. 2022 Nov;78(11):1711-1725. doi: 10.1007/s00228-022-03375-2. Epub 2022 Aug 31.
8
Specialized psychiatric services: patient characteristics, referral practice and length of stay in a representative clinical sample 2010-2016.专业精神科服务:2010 - 2016年代表性临床样本中的患者特征、转诊实践及住院时间
Int J Dev Disabil. 2018 Mar 15;65(4):277-284. doi: 10.1080/20473869.2018.1438961.
9
Caregiver-Reported Pain Management Practices for Individuals With Cerebral Palsy.照顾者报告的脑瘫患者疼痛管理实践
Arch Rehabil Res Clin Transl. 2021 Jan 18;3(1):100105. doi: 10.1016/j.arrct.2021.100105. eCollection 2021 Mar.
10
Barriers to medication adherence for rural patients with mental disorders in eastern China: a qualitative study.中国东部农村地区精神障碍患者药物治疗依从性障碍的定性研究。
BMC Psychiatry. 2021 Mar 8;21(1):141. doi: 10.1186/s12888-021-03144-y.